Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era by Shanti Pather, Alexander Muik, Ruben Rizzi, Federico Mensa

Connect to this object online.

Developing variant-adapted COVID-19 vaccines to improve protection against Omicron and other recent variants: a plain language summary by Shanti Pather, Alexander Muik, Ruben Rizzi, Federico Mensa

Connect to this object online.

Characterizing complex and competing drug-drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine by Matthew P. Kosloski, Hong Li, Stanley Wang, Federico Mensa, Jens Kort, Wei Liu

Connect to this object online.

P62 High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1-6 patients without cirrhosis by Massimo Puoti, Graham Foster, Stanley Wang, David Mutimer, Edward Gane, Christophe Moreno, Ting Tsung Chang, SamS Lee, Rui Marinho, Jean-Francois DuFour, Stanislas Pol, Christophe Hezode, Stuart C. Gordon, Simone I. Strasser, Paul J. Thuluvath, Ran Liu, Tami Pilot-Matias, Federico Mensa

Connect to this object online.

P49 MAGELLAN-1, PART 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure by Fred Poordad, Stanislas Pol, Armen Asatryan, Maria Buti, David Shaw, Christophe Hézode, Franco Felizarta, Robert W. Reindollar, Stuart C. Gordon, Stephen Pianko, Michael W. Fried, David E. Bernstein, Joel Gallant, Chih-Wei Lin, Yang Lei, Teresa I. Ng, Tami Pilot-Matias, Jens Kort, Federico Mensa

Connect to this object online.